Integrative AI Guided Discovery of Phytochemical Based Therapeutics Targeting Infectious And Non-Infectious Diseases: A Molecular and Immunological Approach Ref.No.SSTCRC2645
1. Introduction
The rise in cancer, chronic inflammatory diseases, antimicrobial resistance (AMR), emerging viral infections, and autoimmune conditions highlights the urgent need for novel therapeutic agents that are effective and safe. Natural compounds derived from plants — phytochemicals — offer an enormous untapped resource with historically proven bioactivity and lower toxicity.
However, drug discovery from natural compounds has been slow due to:
-Lack of precise molecular targets.
-Time-consuming experimental screening.
-Poor integration of computational tools with lab-based validation.
We propose a unified pipeline that:
-Uses AI-based target prediction and compound-screening.
-Investigates the molecular mechanisms and immune pathways affected by selected diseases.
-Identifies key biomarkers for diagnostics and therapeutic targeting.
-Validates candidate phytochemicals in in vitro (cell lines, organoids) and in vivo (murine or zebrafish models).
This integrative approach could reduce the timeline for drug discovery and contribute to effective, safer, and affordable treatment options.
2. Objectives
Primary Objective
To identify and validate novel phytochemical compounds with therapeutic potential against selected infectious and non-infectious diseases using AI, molecular biology, and immunological profiling.
Secondary Objectives
-To characterize molecular and immunological profiles of disease models.
-To use AI for screening phytochemicals against molecular targets.
-To perform in vitro cytotoxicity, efficacy, and mechanistic studies.
-To validate lead compounds in in vivo models.
-To assess bioavailability, toxicity, and immunomodulatory potential of selected compounds.
3. Cooperation Required
Financial or laboratory space in any university.
4. Benefits
It gives a highly effective drug to treat cancer, and another infectious and non-infectious diseases. Not only for Asian community but also to the world.
5. Outputs
-A ranked list of 10–15 phytochemicals with strong predicted binding to disease targets.
-Detailed molecular and immune pathway analysis of disease models.
-At least 3–5 compounds with proven efficacy in in vitro models.
-At least 2 lead candidates validated in in vivo models with immunomodulatory effects.
-Publications in high-impact journals.
-Possibility of patent filing and clinical translation.
-Patents